Brought by three pediatric physician practices, the lawsuit claimed that physicians, medical practices, vaccine distributors/wholesalers, and health systems that bought Menactra directly from Sanofi paid inflated prices for quadrivalent meningococcal vaccines due to Sanofi’s alleged anticompetitive conduct.
Eligibility Requirements
All persons or entities in the United States and its territories that purchased Menactra directly from Sanofi Pasteur Inc. or its divisions, subsidiaries, predecessors, or affiliates (e.g., VaxServe, Inc.).
